Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 16/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936204 | 0.77 | SLC6A3 (1.00) | SLC6A3SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL30624700 | 0.76 | SLC6A3 (0.97) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL11614822 | 0.75 | SLC6A2 (0.50) | SLC6A3SLC6A2HSP90AA1LMNA | |
| SCHEMBL11614824 | 0.75 | SLC6A2 (0.50) | SLC6A3SLC6A2HSP90AA1LMNA | |
| SCHEMBL8431652 | 0.72 | SLC6A3 (0.53) | SLC6A3SLC6A2HSP90AA1SLC6A4KDM4E | |
| SCHEMBL21271156 | 0.70 | SLC6A3 (0.83) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL15067033 | 0.69 | KDM4E (0.89) | KDM4ELMNA | |
| SCHEMBL15068256 | 0.69 | KDM4E (0.89) | KDM4ELMNA | |
| SCHEMBL15068257 | 0.69 | KDM4E (0.89) | KDM4ELMNA | |
| SCHEMBL14068917 | 0.69 | SLC6A2 (0.52) | SLC6A3SLC6A2HSP90AA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) | 2008-09-25 | — | — | US | claimed |
| EP-1670755-A4 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | HARVARD COLLEGE (US) | 2007-02-28 | — | — | EP | claimed |
| EP-1670755-A2 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | President And Fellows of Harvard College (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005034878-A2 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-04-21 | — | — | WO | claimed |
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | PRESIDENT AND FELLOW OF HARVARD COLLEGE (US) | 2008-09-25 | — | — | US | disclosed |
| EP-1670755-A4 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | HARVARD COLLEGE (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1670755-A2 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | President And Fellows of Harvard College (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005034878-A2 | PYROVALERONE ANALOGS AND THERAPEUTIC USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234498-A1 | Pyrovalerone Analogues and Therapeutic Uses Thereof | SLC6A2, SLC6A4, SLC6A3 | SLC6A3 3/4885SLC6A2 1/4885HSP90AA1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.